Results 51 to 60 of about 46,447 (205)
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
Frontiers in Pharmacology, 2020 Irinotecan is widely used in the treatment of metastatic colorectal cancer (mCRC) despite its severe toxicities. Toxicity is often associated with the UGT1A1*28/*28 genotype.
Pau Riera +9 more
doaj +1 more source
The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis. [PDF]
PLoS ONE, 2015 Intestinal mucositis is a common side effect of irinotecan-based anticancer regimens. Mucositis causes cell damage, bacterial/endotoxin translocation and production of cytokines including IL-1 and IL-18.
Deysi V T Wong +14 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum +5 more
wiley +1 more source
BMC CancerBackground Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastric cancer (AGC)
Sung Hee Lim +20 more
doaj +1 more source
ADMET and DMPK, 2015 We have recently demonstrated that the oral bioavailability of irinotecan (80 mg/kg) can be increased at least 7-fold by co-administration of the P-gp blocker verapamil (25 mg/kg, Oral).
Tripta Garg +3 more
doaj +1 more source
Cancer Nexus, EarlyView.This graphical abstract summarizes the post‐pCR clinical pathway in locally advanced rectal cancer. After neoadjuvant radiotherapy and systemic therapy followed by surgery, patients achieving pCR (ypT0N0) generally have durable disease control, although residual risks of local and distant recurrence remain. Risk assessment, guideline‐based surveillance,
Jia‐ang Wang +3 more
wiley +1 more source
PharmaceuticsBackground/Objectives: Irinotecan is used in monotherapy or combined with other drugs for treating different cancer streams. SN-38, the active metabolite of irinotecan, is 70% inactivated by the uridine diphosphate (UDP) glucuronosyltransferase family 1 ...
Xando Díaz-Villamarín +9 more
doaj +1 more source
International Journal of Cancer, EarlyView.ABSTRACT Adjuvant chemotherapy can improve outcomes for patients who have undergone lung cancer resection, and perioperative rehabilitation may help maintain the physical condition necessary to receive adjuvant chemotherapy. This observational cohort study investigated the impact of perioperative rehabilitation on the administration of postoperative ...
Shinkichi Takamori +12 more
wiley +1 more source
Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer
International Journal of Cancer, EarlyView.ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue +6 more
wiley +1 more source